间皮素作为癌症免疫治疗的生物标志物和治疗靶点
Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer.
癌症仍是一个关键的全球健康问题,原因在于发现晚、耐药和高死亡率。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:An immunosuppressive scoring system to predict recurrence and assist in decision regarding postoperative adjuvant treatment in gastric cancer.
An immunosuppressive scoring system to predict recurrence and assist in decision regarding postoperative adjuvant treatment in gastric cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
免疫微环境抑制是胃癌(GC)患者术后肿瘤复发的主要原因。本研究采用免疫组织化学和多色免疫荧光染色,对来自三个中心的825例胃癌患者的免疫抑制指标和免疫生物标志物进行评估。我们基于六项免疫抑制指标的表达,利用LASSO Cox回归构建了免疫抑制复发评分(IRS),并发现IRS及基于IRS的列线图在预测复发方面具有显著准确性和可靠性。此外,IRS升高与局部区域复发及术后辅助化疗失败相关。进一步发现,IRS升高表明浸润边缘CD8+TIL(肿瘤浸润淋巴细胞)的抗肿瘤效应受到抑制。因此,我们提出IRS可通过区分免疫抑制状态来预测GC患者的复发结局,有助于个体化辅助治疗方案的选择。
Inhibition of the immune microenvironment is the main cause of tumor recurrence after surgery in patients with gastric cancer (GC). In this study, immunohistochemistry and multiple immunofluorescence staining were used to evaluate immunosuppressive indicators and immune biomarkers in 825 patients with gastric cancer from three centers.
We constructed an immunosuppressive recurrence score (IRS) using LASSO Cox regression based on the expression of six immunosuppressive indicators and found that the IRS and IRS-based nomogram were significantly accurate and reliable in predicting recurrence.
Moreover, an elevated IRS was associated with locoregional recurrence and postoperative adjuvant chemotherapy failure.
Furthermore, an increase in IRS indicated inhibition of the antitumor effect of CD8 + tumor-infiltrating lymphocytes in the invasive margin.
Thus, we propose that the IRS can predict the recurrence outcome of patients with GC by distinguishing the immunosuppressive status, which is helpful in the selection of individualized adjuvant treatment plans.
在 PubMed 查看 → 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。